Journal Article

New Therapies for Hepatitis C Virus Infection

Vincent Soriano, Marion G. Peters and Zeuzem Stefan

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 48, issue 3, pages 313-320
Published in print February 2009 | ISSN: 1058-4838
Published online February 2009 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/595848
New Therapies for Hepatitis C Virus Infection

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Chronic hepatitis C virus (HCV) infection remains a global health threat with ∼175 million carriers worldwide. Currently, treatment consists of pegylated interferon alfa plus ribavirin for 12–72 weeks, depending on HCV genotype, baseline viral load, and initial virological response to therapy. Serious adverse effects and limited sustained virological responses with this therapy warrant the need for novel HCV therapies. Specifically targeted antiviral therapies designed to inhibit the HCV serine protease and the RNA-dependent RNA polymerase have recently entered clinical development. Herein, the main characteristics of these new antiviral agents and the most important challenges arising with their use—namely, toxicities and rapid selection of resistance—are discussed.

Journal Article.  5754 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.